CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 25 enrolled
Drug / intervention
Ipilimumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03912064
NCT03912064Phase 1Active
CompareCT.gov

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Dana-Farber Cancer Institute·interventional·Posted Apr 11, 2019·Updated Jan 5, 2026

In Brief

A Phase 1 clinical trial evaluating Ipilimumab and CD25hi Treg depleted DLI for Acute Myeloid Leukemia and 4 related conditions. Active but no longer recruiting, targeting 25 participants across 2 sites.

Detailed Summary

In this research study, our main goal for the ipilimumab portion of the study is to determine the highest dose of ipilimumab that can be given safely in several courses and to determine what side effects are seen in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), Chronic Myelomonocytic Leukemia (CMML), or Myelofibrosis (MF).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia, Myelofibrosis
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 1Active
20202021202220232024202520262027
First PostedApr 11, 2019
Enrollment StartJul 10, 2019
Primary CompletionMay 24, 2024
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 7.2 years ago

Interventions

Ipilimumabdrug

Ipilimumab is an antibody that acts against CTLA-4

CD25hi Treg depleted DLIbiological

Donor lymphocyte product